245 related articles for article (PubMed ID: 22612853)
1. Early detection of pharmacovigilance signals with automated methods based on false discovery rates: a comparative study.
Ahmed I; Thiessard F; Miremont-Salamé G; Haramburu F; Kreft-Jais C; Bégaud B; Tubert-Bitter P
Drug Saf; 2012 Jun; 35(6):495-506. PubMed ID: 22612853
[TBL] [Abstract][Full Text] [Related]
2. Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area.
Grundmark B; Holmberg L; Garmo H; Zethelius B
Eur J Clin Pharmacol; 2014 May; 70(5):627-35. PubMed ID: 24599513
[TBL] [Abstract][Full Text] [Related]
3. Pharmacovigilance data mining with methods based on false discovery rates: a comparative simulation study.
Ahmed I; Thiessard F; Miremont-Salamé G; Bégaud B; Tubert-Bitter P
Clin Pharmacol Ther; 2010 Oct; 88(4):492-8. PubMed ID: 20811349
[TBL] [Abstract][Full Text] [Related]
4. Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling.
Alvarez Y; Hidalgo A; Maignen F; Slattery J
Drug Saf; 2010 Jun; 33(6):475-87. PubMed ID: 20486730
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two drug safety signals in a pharmacovigilance data mining framework.
Tubert-Bitter P; Bégaud B; Ahmed I
Stat Methods Med Res; 2016 Apr; 25(2):615-29. PubMed ID: 23070598
[TBL] [Abstract][Full Text] [Related]
6. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.
Almenoff JS; LaCroix KK; Yuen NA; Fram D; DuMouchel W
Drug Saf; 2006; 29(10):875-87. PubMed ID: 16970511
[TBL] [Abstract][Full Text] [Related]
7. Implementation of an automated signal detection method in the French pharmacovigilance database: a feasibility study.
Pizzoglio V; Ahmed I; Auriche P; Tuber-Bitter P; Haramburu F; Kreft-Jaïs C; Miremont-Salamé G;
Eur J Clin Pharmacol; 2012 May; 68(5):793-9. PubMed ID: 22143912
[TBL] [Abstract][Full Text] [Related]
8. Contribution of Causality Assessment for an Automated Detection of Safety Signals: An Example Using the French Pharmacovigilance Database.
Berbain T; Pariente A; Miremont-Salamé G; Grandvuillemin A; Micallef J; Chouchana L; Benkebil M; Théophile H;
Drug Saf; 2020 Mar; 43(3):243-253. PubMed ID: 31974775
[TBL] [Abstract][Full Text] [Related]
9. Bayesian pharmacovigilance signal detection methods revisited in a multiple comparison setting.
Ahmed I; Haramburu F; Fourrier-Réglat A; Thiessard F; Kreft-Jais C; Miremont-Salamé G; Bégaud B; Tubert-Bitter P
Stat Med; 2009 Jun; 28(13):1774-92. PubMed ID: 19360795
[TBL] [Abstract][Full Text] [Related]
10. Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations.
Caster O; Aoki Y; Gattepaille LM; Grundmark B
Drug Saf; 2020 May; 43(5):479-487. PubMed ID: 32008183
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of three signal-detection algorithms using a highly inclusive reference event database.
Hochberg AM; Hauben M; Pearson RK; O'Hara DJ; Reisinger SJ; Goldsmith DI; Gould AL; Madigan D
Drug Saf; 2009; 32(6):509-25. PubMed ID: 19459718
[TBL] [Abstract][Full Text] [Related]
12. False discovery rate estimation for frequentist pharmacovigilance signal detection methods.
Ahmed I; Dalmasso C; Haramburu F; Thiessard F; Broët P; Tubert-Bitter P
Biometrics; 2010 Mar; 66(1):301-9. PubMed ID: 19432790
[TBL] [Abstract][Full Text] [Related]
13. Pilot evaluation of an automated method to decrease false-positive signals induced by co-prescriptions in spontaneous reporting databases.
Avillach P; Salvo F; Thiessard F; Miremont-Salamé G; Fourrier-Reglat A; Haramburu F; Bégaud B; Moore N; Pariente A;
Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):186-94. PubMed ID: 23670805
[TBL] [Abstract][Full Text] [Related]
14. Class-imbalanced subsampling lasso algorithm for discovering adverse drug reactions.
Ahmed I; Pariente A; Tubert-Bitter P
Stat Methods Med Res; 2018 Mar; 27(3):785-797. PubMed ID: 27114328
[TBL] [Abstract][Full Text] [Related]
15. Criteria revision and performance comparison of three methods of signal detection applied to the spontaneous reporting database of a pharmaceutical manufacturer.
Matsushita Y; Kuroda Y; Niwa S; Sonehara S; Hamada C; Yoshimura I
Drug Saf; 2007; 30(8):715-26. PubMed ID: 17696584
[TBL] [Abstract][Full Text] [Related]
16. Benefits of combining change-point analysis with disproportionality analysis in pharmacovigilance signal detection.
Trinh NTH; Solé E; Benkebil M
Pharmacoepidemiol Drug Saf; 2019 Mar; 28(3):370-376. PubMed ID: 29992679
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of statistical association measures for the automatic signal generation in pharmacovigilance.
Roux E; Thiessard F; Fourrier A; Bégaud B; Tubert-Bitter P
IEEE Trans Inf Technol Biomed; 2005 Dec; 9(4):518-27. PubMed ID: 16379369
[TBL] [Abstract][Full Text] [Related]
18. Data mining spontaneous adverse drug event reports for safety signals in Singapore - a comparison of three different disproportionality measures.
Ang PS; Chen Z; Chan CL; Tai BC
Expert Opin Drug Saf; 2016 May; 15(5):583-90. PubMed ID: 26996192
[TBL] [Abstract][Full Text] [Related]
19. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
[TBL] [Abstract][Full Text] [Related]
20. Impact of adverse event reports from marketing authorization holder-sponsored patient support programs on the performance of signal detection in pharmacovigilance.
Lee I; Lee TA; Crawford SY; Kilpatrick RD; Calip GS; Jokinen JD
Expert Opin Drug Saf; 2020 Oct; 19(10):1357-1366. PubMed ID: 32662668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
